Evening of 5th March 2018
Nicox Conference & Cocktail
Meet the Management of Nicox, an international ophthalmology company, with two products approved for commercialization in the United States by licensed third parties, developing innovative solutions for maintaining vision and improving eye health. The company’s strategy is to maximize the potential of its research platform through internal developments and collaborations with leading pharmaceutical companies.
Evening of 21st March 2018
Transgene Conference & Cocktail
Transgene develops innovative immunotherapies against cancers and infectious diseases. Our approach aims to stimulate the immune responses of patients to attack diseased cells on multiple fronts. Five products are in Phase 1 to 3 of clinical trials. With our Invir.IOTM platform, we are designing a new generation of multifunctional oncolytic viruses. Meet our management to discuss our achievements of 2017 and prospects of 2018/2019.
Evening of 21st February 2018
Sensorion Conference & Cocktail
Meet the Management of Sensorion, a biotechnology company that develops first-in-class drugs for the treatment of inner ear diseases such as severe vertigo, tinnitus or hearing loss. There is still no cure for these highly disabling conditions that affect more than 140 million people worldwide and result in very high societal costs.
Evening of 30th January 2018
Cellnovo Conference & Cocktail
Meet the management of Cellnovo Group SA, a company that develops and distributes the world’s first all-in-one diabetes management system, including a ground-breaking insulin micro-pump. Cellnovo contributes to improving and simplifying the life of diabetic patients and participates in several major projects in the artificial pancreas.
Evening of 16th November 2017
Inauguration evening of Par'Immune
Par’Immune is a biopharmaceutical company co-founded by Professor Monique Capron and Dr. Abderrahim Lachgar, dedicated to the development of an innovative drug candidate of parasitic origin, the P28GST. This candidate targeting autoimmune and inflammatory diseases is currently being evaluated in a Phase 2a clinical trial in patients with Crohn’s disease. In early 2018, the company will initiate its development plan to conduct two Phase 2b clinical trials in various inflammatory diseases.
EVENING OF 17th OCTOBER 2017
PrimaDiag Conference & Cocktail
PrimaDiag is a French company developing and commercializing compact robotic platforms for the rapid automation of a wide variety of protocols in the field of molecular biology and genomics.
Diavein Conference Cocktail
Diavein is a start-up developing and marketing an electro-stimulation device of the vascular system. Diavein aims to relieve the sickle cell disease, the most common orphan genetic disease in the world (5 million people affected). It is characterized in particular by vaso-occlusive crises, due to obstructions of the blood vessels, very painful and too often fatal.
Evening of 3rd October 2017
DEINOVE Conference & Cocktail
Presentation by the management of DEINOVE, a biotechnology company discovering, developing and producing compounds from the microbial world that are of interest to the health, nutrition and cosmetics industries.
It focuses on two major families of molecules: antibiotics and carotenoids (antioxidants) and collaborates in parallel with industrial groups seeking innovation.
Evening of 27th June 2017
PRE-IPO, INVEST SECURITIES
NH TherAguix Conference & Cocktail
Presentation by the managemet of NH TherAguix,a pharmaceutical company developing innovative nanomedicine that improves the effectiveness of radiotherapy and reduces side effects without changing clinical practice. Its AGuIX® drug, in clinical phase 1, is a non-invasive, personalized solution that improves cancer imaging and treatment
Medsteer Conference & Cocktail
Presentation by the management of Medsteer, a company developing an innovative medical device for the anesthetists of the operating room. The EasyTIVA system, thanks to a patented algorithm based on cerebral activity, allows to regulate in real time the depth of the general anesthesia of the patient and to reduce the postoperative side effects. Patients wake up quickly and comfortably.
Evening of 23rd May 2017
ERYTECH Conference & Cocktail
Presentation by the management of ERYTECH, a biopharmaceutical company in clinical stage that develops innovative therapies in rare forms of cancers and orphan diseases.
Based on its proprietary platform, ERYCAPS, which uses a new technology to encapsulate drugs (especially enzymes) in red blood cells, ERYTECH has developed a portfolio of candidate products addressing markets with strong medical needs.
Evening of 18th May 2017
Quantum Genomics Conference & Cocktail
Presentation by the management of Quantum Genomics, a company developing new therapies for unmet medical needs in the field of high blood pressure and heart failure.
During this evening, the managers will present the latest news of the company including the creation of the Shareholders’ Club.
Evening of 22nd February 2017
LLTech Conference & Cocktail
Presentation by the management of LLTech, an innovative medical imaging company, specializing in real-time cancer diagnosis in the radiology and surgery room by CT SCAN OPTIQUE.
LLTech is already commercializing a system and is aiming for a $ 5 billion potential market with the development of a version intended for clinical routine in diagnosis (qualification of biopsies) and in cancer surgery (margins in real time).
Evening of 13th December 2016
Biophytis Conference & Cocktail
Presentation by the management of Biophytis, a company specializing in diseases related to the challenge of aging, especially those affecting muscular and visual functions.
It has a portfolio of first-in-class drug candidates to treat certain indications of sarcopenia and AMD, now without treatment.
Evening of 8th November 2016
Quantum Genomics Conference Cocktail
Meet the management of Quantum Genomics, a company developing new therapies for unmet medical needs in the field of high blood pressure and heart failure.
Evening of 5th July 2016
Cerenis Therapeutics Conference Cocktail
Meet Jean-Louis Dasseux, PhD, MBA, founder and CEO of Cerenis Therapeutics, inventor of innovative strategies based on HDL (the “good cholesterol”) for the treatment of cardiovascular and metabolic diseases.